Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Fan Y, Drilon A, Chiu CH, Loong HHF, Siena S, Krzakowski M, Dziadziuszko R, Zeuner H, Xue C, Krebs MG. Fan Y, et al. Among authors: xue c. Clin Lung Cancer. 2024 Mar;25(2):e81-e86.e4. doi: 10.1016/j.cllc.2023.12.001. Epub 2023 Dec 7. Clin Lung Cancer. 2024. PMID: 38245456 Free PMC article.
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ. Brezden-Masley C, et al. Among authors: xue c. Breast Cancer Res Treat. 2021 Jan;185(2):507-515. doi: 10.1007/s10549-020-05960-4. Epub 2020 Oct 16. Breast Cancer Res Treat. 2021. PMID: 33064230 Free PMC article.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Zhukova N, Schachter J, Yan Y, Caro I, Hertig C, Xue C, Kusters L, McArthur GA, Gutzmer R. Ascierto PA, et al. Among authors: xue c. Lancet Oncol. 2023 Jan;24(1):33-44. doi: 10.1016/S1470-2045(22)00687-8. Epub 2022 Nov 29. Lancet Oncol. 2023. PMID: 36460017 Clinical Trial.
The inhibitory effect of Hypericum japonicum on H9N2 avian influenza virus.
Hu H, Li J, Zheng S, Zhao K, Xia Y, Wei X, Han M, Zhao Y, Peng O, Zhao Z, Chen Z, Su W, Cao Y, Wang Y, Xue C. Hu H, et al. Among authors: xue c. Adv Biotechnol (Singap). 2024 Nov 6;2(4):41. doi: 10.1007/s44307-024-00046-4. Adv Biotechnol (Singap). 2024. PMID: 39883224 Free PMC article.
4,569 results